

**UNITED STATES DEPARTMENT OF COMMERCE****United States Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

col

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/005,711 01/12/98 BROCIA

R

HM22/0601

CHERYL H. AGRIS
ATTORNEY AT LAW
P.O. BOX 806
PELHAM NY 10803

EXAMINER

GITOMER, R

ART UNIT

PAPER NUMBER

1623

18

DATE MAILED:

06/01/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No.
09/005,711

Applicant(s)

Brocia

Examiner
Ralph Gitomer

Art Unit
1623



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on amendment received 4/17/2001.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 23-30 is/are pending in the application.
- 4a) Of the above, claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 23-30 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claims _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are objected to by the Examiner.
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

- 13) ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
- a) ☐ All b) ☐ Some* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- *See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

- 15) ☐ Notice of References Cited (PTO-892)
- 16) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 17) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s). 17
- 18) ☒ Interview Summary (PTO-413) Paper No(s). 17
- 19) ☐ Notice of Informal Patent Application (PTO-152)
- 20) ☐ Other:

The amendment, Declaration and IDS received 4/17/01 have been entered and claims 23-30 are currently pending in this application. It would appear this application claims priority to
5 no other applications, therefor a priority date of 1/12/98 is granted.

A new specification has been submitted which is greatly modified from the original specification. No statement regarding new matter is found, the new specification was not requested,
10 therefor it is not entered.

In view of the all new claims with many new issues under 35 USC 112, a proper search of the claims as submitted is not possible at this time. No search has been performed.

15
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by
20 a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
25

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be
30 commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 23-30 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 23-36 of U.S. Patent No. 5,770,355. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims of `355 are directed to a lipid transfer protein and the present claims are more broadly directed to a protein that transports.

Claims 23-30 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The application as originally filed does not enable the newly submitted claims which appear to be directed to an assay with some fluorescent component. It would appear there is a chemical reaction cascade involved in the invention, but none is shown. Note on page 9 last full paragraph, such a method is not understood in context. On page 10 second paragraph last line, it is not seen CETP mass is measured. On page 11 last paragraph, ~~✕~~The normalization factor includes a colorizing factor that reacts in response to the normalizing factor of choice.~~✕~~ The example on page 12 is insufficiently detailed to follow. No data of any sort nor results of any determination are found in the specification. As written, one of skill in this art could not

perform the claimed invention by following the teachings of the specification.

Claims 23-30 are rejected under 35 U.S.C. § 112, second
5 paragraph, as being indefinite for failing to particularly point
out and distinctly claim the subject matter which applicant
regards as the invention. Each of the following applies in all
occurrences.

10 In claim 23(b) ~~an~~ an acceptor dependent concentration light
emission intensity quencher~~is~~ is not understood in context. ~~Of~~
said light emission intensity~~lacks~~ lacks antecedent basis. ~~A~~
normalization factor~~in~~ in context is not understood as to what it
is and what it does. Claim 23 is directed to measuring activity
but lacks any such step to perform that function. Claim 23 lacks
15 any correlating step. In claim 24 ~~the~~ the donor particle~~lacks~~ lacks
antecedent basis. Claim 25 is not understood. In claim 27(ii)
~~a~~ a protein dependent concentration light emission intensity
quencher~~is~~ is not understood in context.

20 The title of the invention is not aptly descriptive. A new
title is required that is clearly indicative of the invention to
which the claims are directed.

Serial No. 09/005,711
Art Unit 1623


-5-

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ralph Gitomer whose telephone number is (703) 308-0732. The examiner can normally be reached on Tuesday-Friday from 8:00 am - 5:00 pm.

5 The examiner can also be reached on alternate Mondays. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Geist can be reached on (703) 308-1701. The fax phone number for this Art Unit is (703) 308-4556. Any inquiry of a general nature or relating to the status of this

10 application should be directed to the Group receptionist whose telephone number is (703) 308-1234. For 24 hour access to patent application information 7 days per week, or for filing applications electronically, please visit our website at www.uspto.gov and click on the button Patent Electronic Business

15 Center for more information.



Ralph Gitomer
Primary Examiner
Group 1623

**RALPH GITOMER
PRIMARY EXAMINER
GROUP 1200**